GlassScriptPhysician profile
Wailma William
NPI 1659954634
$756.63
in general payments reported to CMS, 2019-2025
18 companies · $380 in 2025
The $380 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $186 · 2024: $191 · 2025: $380.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $658 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $657.63 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $156.87 | 2023-2025 | Darzalex, Tecvayli, Rybrevant |
| Beigene USA, INC. | $125.00 | 2024 | Brukinsa |
| Novartis Pharmaceuticals Corporation | $94.91 | 2025 | |
| Daiichi Sankyo INC. | $56.89 | 2025 | Enhertu |
| Glaxosmithkline, LLC. | $32.08 | 2025 | Zejula, Jemperli |
| Tms Neurohealth Centers INC. | $30.97 | 2025 | Tms Neurohealth Centers INC. |
| Incyte Corporation | $25.88 | 2025 | Monjuvi |
| Sobi, INC | $25.29 | 2024 | |
| Janssen Scientific Affairs, LLC | $23.98 | 2025 | Spravato |
| Pfizer INC. | $23.84 | 2024 | |
| Servier Pharmaceuticals LLC | $23.74 | 2023 | |
| G1 Therapeutics, INC. | $21.83 | 2023 | Cosela |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $21.05 | 2025 | Caplyta |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $20.81 | 2025 | |
| Alkermes, INC. | $20.59 | 2025 | Lybalvi |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $18.16 | 2025 | Lynozyfic |
| Tolmar, INC. | $17.55 | 2023 | |
| Sanofi-Aventis U.S. LLC | $17.19 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wailma William listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.